The cascading effects of Covid-19 restrictions hamper efforts to cope with seasonal outbreaks of dengue, an incurable, mosquito-borne disease that is also known as “breakbone fever" for its severely painful symptoms.
French drug maker Sanofi had earlier revealed that Dengvaxia - the world's first dengue vaccine might increase the risk of severe disease in people who had never been exposed to the virus.
The country halts use of Dengvaxia vaccine after French pharma Sanofi says its drug might, in some cases increase risk of severe dengue in recipients not previously infected by the virus.
Hospitals in Sri Lanka are overwhelmed as the government struggles to control the virus which can develop into a deadly hemorrhagic fever.
Over 76,000 people have been infected by the mosquito-borne disesase in the first six months of this year, a record figure that far surpasses last year's total of 55,000.
Subscribe to our Youtube channel for all latest in-depth, on the ground reporting from around the world.
Copyright © 2023 TRT World.